

Mallinckrodt Inc.



Via Federal Express

Br 2

January 7, 2010

U.S. Nuclear Regulatory Commission
Region I
Nuclear Materials Licensing Section
475 Allendale Road
King of Prussia, PA 19406-1415

03032952

RE: Mallinckrodt Inc.'s Request for Approval to Transfer License #**24-04206-15MD** for the pharmacy facility located at **180 Pepes Farm Road, Milford, CT 06460**

Dear Sir or Madam:

This letter is to notify you that on or about December 16, 2009 Mallinckrodt Inc. entered into an Asset Purchase Agreement to sell the above referenced nuclear pharmacy operation to Triad Isotopes, Inc. (Triad). The closing of this transaction is tentatively scheduled for March 31, 2010, subject to the approval of all applicable regulatory agencies, including the NRC. A copy of a press release dated December 17, 2009 is attached for reference purposes and it describes the proposed transaction in greater detail.

By this letter, Mallinckrodt Inc. is requesting NRC's approval to transfer the above referenced license to Triad as of March 31, 2010. On the date the transaction closes, an additional correspondence will be sent to your office, confirming that the change of ownership has been finalized. As required by 10 CFR §30.34 (b), Mallinckrodt is providing the following information to assist the NRC in evaluating this request for approval of this license transfer.

1. The new name of the licensed organization and their headquarters address;

Triad Isotopes, Inc.
200 South Orange Avenue, Suite 2100
Orlando, Florida 32801

2. The new licensee contact and telephone number(s) to facilitate communications;

William P. McCormick
Senior Vice-President/General Counsel
Triad Isotopes, Inc.
200 South Orange Avenue, Suite 2100
Orlando, Florida 32801
Phone- 407-455-6704
Fax- 407-455-6732
E-mail: wmccormick@triadisotopes.com

2010 JAN 11 AM 10: 29
RECEIVED
REGION 1

144368

3. List any changes in personnel having control over licensed activities and any changes in personnel named in the license;

Triad does not anticipate any changes to the current Radiation Safety Officer or authorized users at the above referenced pharmacy facility as a result of this transaction. If any changes do occur, Triad will promptly notify NRC, in writing. A listing of the Triad corporate officers and directors is attached hereto as Exhibit "A."

4. An indication of whether the transferor will remain in non-licensed business without a license.

No, but Mallinckrodt Inc. (d/b/a Covidien) will remain in the business of the bulk manufacture of radiopharmaceutical products and distribution to nuclear pharmacies of bulk product and will retain an NRC license for its Maryland Heights, MO manufacturing (License # 24-04206-01MD/24-04206-05MD) and Hazelwood, MO Research and Development operations (License # 24-17450-01) in connection with those activities. Mallinckrodt Inc. is also undergoing licensed decommissioning activities at its St. Louis, MO facility for a different NRC license. Mallinckrodt Inc. will have no involvement with the ownership or operation of the above referenced, nuclear pharmacy after the closing of the transaction, on or about March 31, 2010.

5. A complete, clear description of the transaction, including any transfer of stocks or assets, mergers, etc., so that legal counsel is able, when necessary, to differentiate between name changes and changes of ownership.

This license transfer is necessary due to a change in ownership of the above referenced nuclear pharmacy. Mallinckrodt will sell all of the assets of the above nuclear pharmacy pursuant to the Asset Purchase Agreement dated December 16, 2009 with Triad. Mallinckrodt Inc. did not transfer any stock and Triad is an independent corporation which currently owns and operates nuclear pharmacies licensed by several agreement states. Triad's current locations are listed at www.triadisotopes.com.

6. A complete description of any planned changes in organization, location, facility, equipment, or procedures.

At this time, Triad has not planned any specific changes to the pharmacy operations. If Triad plans to modify or change the organizational structure, Triad will advise NRC at that time. Triad understands that any proposed changes will need to be communicated to the NRC.

7. A detailed description of any changes in the use, possession, location or storage of licensed materials.

There are no changes anticipated in the use, possession, location, or storage of the licensed materials.

8. Any changes in organization, location, facilities, equipment, procedures, or personnel that would require a license amendment even without the change of ownership.

There are no such changes to the licenses that fall within this category.

9. An indication of whether all surveillance items and records will be current at the time of transfer. A description of the status of all surveillance requirements and records should also be provided.

There should be no changes in location of records because of the sale. All pertinent and required records applicable to pharmacy operations will be retained at the pharmacy or provided to Triad at the time of final closing.

10. Confirmation that all records concerning the safe and effective decommissioning of the facility, pursuant to 10 CFR 30.35(g), 40.36(f), 70.25(g), and 72.30(d); public dose; and waste disposal by release to sewers, incineration, radioactive spills, and on-site burials, have been transferred to the new licensee, if licensed activities will continue at the same location, or to the NRC for license termination.

Refer to the response offered in Item 9.

11. A description of the status of the facility. Specifically, the presence or absence of contamination should be documented. If contamination is present, will decontamination occur before transfer? If not, does the successor company agree to assume full liability for the decontamination of the facility or site?

Triad, as the successor company, has agreed to take possession of each facility in its current condition, since the facility will continue operation as a nuclear pharmacy. Responsibility for pre-closing and post closing environmental issues is apportioned between Mallinckrodt Inc. and Triad, in the Asset Purchase Agreement dated December 16, 2009. The successor company will assume full liability for final decommissioning of the above referenced facility if it is shut down at any time in the future.

12. A description of any decontamination plans, including financial assurance arrangements of the transferee, as specified in 10 CFR 30.35, 40.36, and 70.25. This should include information about how the transferee and transferor propose to divide the transferee's assets, and responsibility for any cleanup needed at the time of transfer.

See response to Item 11.

13. Confirmation that the transferee agrees to abide by all commitments and representations previously made to the NRC by the transferor. These include, but are not limited to: maintaining decommissioning records required by 10 CFR 30.35(g); implementing decontamination activities and decommissioning of the site; and completing corrective actions for open inspection items and enforcement actions.

All of the existing license conditions will be maintained, and constraints, conditions, requirements, representations and commitments identified in the above referenced license

will be followed by Triad upon license transfer. All of the existing radiation safety programs will be maintained and followed by Triad, as required by applicable regulation.

14. Documentation that the transferor and transferee agree to the change in ownership or control of the licensed material and activity, and the conditions of transfer; and the transferee is made aware of all open inspection items and its responsibility for possible resulting enforcement actions.


Refer to response offered in Item 13. Triad has been notified of any open inspection items and subject to the terms of the Asset Purchase Agreement dated December 16, 2009, has agreed to be responsible for resolving any existing, open issues in connection with the transfer of the assets, including the above-referenced license.

15. A commitment by the transferee to abide by all constraints, conditions, requirements, representations, and commitments identified in the existing license.

Triad agrees to perform and abide by all of the constraints, conditions, requirements, representations and commitments identified in the above-referenced license. In addition, please refer to the response offered in Item 14.

Please note that we would appreciate your expeditious review and approval of the above-referenced license transfer approval request. If you have any questions regarding the foregoing, please contact Kay Yoder, Mallinckrodt's Director of Radiation, Environment, Safety and Health at 314-654-7432 or Patricia Duft, Mallinckrodt's Chief EHS Counsel at 314-654-6314. Bill McCormick, Triad's General Counsel, is also available at 407-455-6704. Thank you for your attention to this matter.

On behalf of Mallinckrodt Inc.;



Patricia H. Duft
Vice-President, Legal

On behalf of Triad Isotopes, Inc.;



William P. McCormick
Senior Vice-President
General Counsel

Enc:

Mallinckrodt Inc. press release dated 12/17/09
Exhibit "A"- Triad Officer and Director List

cc: file

Bill McCormick (Triad)
Brigette Nelson (Triad)
Shannon Julian (Triad)

Joseph Remez-Gurrette, Lead RPh – Milford
Richard Hylinski, RSO - Milford



positive results for life™

News Release

Covidien Announces Definitive Agreement to Sell U.S. Radiopharmacies

DUBLIN, Dec 17, 2009 (BUSINESS WIRE) -- Covidien (NYSE: COV), a leading global provider of healthcare products, today announced a definitive agreement to sell its radiopharmacies in the United States to Triad Isotopes, Inc. of Orlando, Florida. Triad operates a network of 26 nuclear radiopharmacies and six cyclotron facilities in the southeast United States. Financial terms of the transaction were not disclosed.

The decision to divest the network of 37 Mallinckrodt radiopharmacies was made following a thorough review and evaluation of a number of strategic alternatives. The decision is consistent with Covidien's strategy to streamline its portfolio and reallocate resources to its faster-growing, higher-margin businesses, where the Company has or can develop a global competitive advantage. The move allows the Company greater focus on continuing to develop and provide quality products that deliver better value and help to improve patient outcomes.

Covidien's radiopharmacy net sales were approximately \$180 million in fiscal 2009.

Completion of the transaction is subject to customary closing conditions, as well as receipt by Triad of necessary state and federal licenses and Triad's ability to secure financing for the transaction, with closing expected during the second calendar quarter of 2010. The transaction is not expected to have a material effect on Covidien's operating income or earnings per share for fiscal 2010 or 2011.

ABOUT COVIDIEN

Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading product lines in three segments: Medical Devices, Pharmaceuticals and Medical Supplies. With 2009 revenue in excess of \$10 billion, Covidien has 42,000 employees worldwide in more than 60 countries, and its products are sold in over 140 countries. Please visit http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.covidien.com&esheet=6122817&lan=en_US&anchor=www.covidien.com&index=1&md5=43c801b654b1891cf4437a6ccfd8d85 to learn more about our business.

FORWARD-LOOKING STATEMENTS

Any statements contained in this communication that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or Company actions to differ materially from what is expressed or implied by these statements. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, the possibility that the transaction will not close or that the closing may be delayed, our ability to effectively introduce and market new products or keep pace with advances in technology, the reimbursement practices of a small number of large public and private insurers, cost-containment efforts of customers, purchasing groups, third-party payers and governmental organizations, intellectual property rights disputes, complex and costly regulation, including healthcare fraud and abuse regulations, manufacturing or supply chain problems or disruptions, rising commodity costs, recalls or safety alerts and negative publicity relating to Covidien or its products, product liability losses and other litigation liability, including legacy Tyco-related litigation, divestitures of some of our businesses or product lines, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, competition, risks associated with doing business outside of the United States, foreign currency exchange rates or potential environmental liabilities. These and other factors are identified and described in more detail in our filings with the SEC. We disclaim any obligation to update these forward-looking statements other than as required by law.

SOURCE: Covidien

Covidien
JoAnna Schooler, 314-654-3543
Director, Communications
Pharmaceuticals
joanna_schooler@covidien.com
or
Coleman Lannum, CFA, 508-452-4343
Vice President
Investor Relations
cole.lannum@covidien.com
or
Bruce Farmer, 508-452-4372
Vice President
Public Relations
bruce.farmer@covidien.com
or
Brian Nameth, 508-452-4363
Director
Investor Relations
brian.nameth@covidien.com

Exhibit "A"

**Triad Isotopes, Inc.
200 South Orange Avenue, Suite 2100
Orlando, Florida 32801
FEIN# 20-5744906**

Officers & Directors of Triad Isotopes, Inc.

Officers

Name and Address	Title
Domenic Anthony Meffe, Jr. 6507 Rosella Ct. Windermere, Fl. 34786	President and Chief Executive Officer
Claudia Noyes Griffiths 1581 Chippewa Trail Maitland, FL 32751	SVP Finance and Administration
William Patrick McCormick 1514 Holly Hill Drive Bethel Park, PA 15102	SVP General Counsel and Secretary
H. Bradley Sloan 3446 Scott Street San Francisco, CA 94123	SVP Assistant Secretary

Directors

Name, Address and Phone Number	Title
Dominic Anthony Meffe, Jr. 6507 Rosella Ct. Windermere, Fl. 34786 Phone- 407-876-5504	Director
H. Bradley Sloan 3446 Scott Street San Francisco, CA 94123 Phone- 415-902-5810	Director
David J. Ament 37 Circuit Road Chestnut Hill, MA 02467 Phone- 617-470-6958	Director

This is to acknowledge the receipt of your letter/application dated

1/7/2010, and to inform you that the initial processing which includes an administrative review has been performed.

NOTIFICATION 24-04206-15MD
There were no administrative omissions. Your application was assigned to a technical reviewer. Please note that the technical review may identify additional omissions or require additional information.

Please provide to this office within 30 days of your receipt of this card

A copy of your action has been forwarded to our License Fee & Accounts Receivable Branch, who will contact you separately if there is a fee issue involved.

Your action has been assigned **Mail Control Number** 144368.

When calling to inquire about this action, please refer to this control number.

You may call us on (610) 337-5398, or 337-5260.